APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Receptor Radionuclide Therapy (PRRT)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchPeptide Receptor Radionuclide Therapy (PRRT) Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Receptor Radionuclide Therapy (PRRT) Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Receptor Radionuclide Therapy (PRRT) Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Peptide Receptor Radionuclide Therapy (PRRT) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Receptor Radionuclide Therapy (PRRT) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Receptor Radionuclide Therapy (PRRT) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Receptor Radionuclide Therapy (PRRT) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Receptor Radionuclide Therapy (PRRT) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Receptor Radionuclide Therapy (PRRT) market include Aurobindo Pharma, Curium Pharmaceuticals, Lantheus, Mundipharma, Bayer and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Peptide Receptor Radionuclide Therapy (PRRT) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Receptor Radionuclide Therapy (PRRT) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Receptor Radionuclide Therapy (PRRT) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Peptide Receptor Radionuclide Therapy (PRRT) market.

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Company

Aurobindo Pharma

Curium Pharmaceuticals

Lantheus

Mundipharma

Bayer

Novartis

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Type

Midgut Neuroendocrine Tumor

Gastroenteropancreatic Neuroendocrine Tumor

Foregut Neuroendocrine Tumor

Hindgut Neuroendocrine Tumor

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Peptide Receptor Radionuclide Therapy (PRRT) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Receptor Radionuclide Therapy (PRRT) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Peptide Receptor Radionuclide Therapy (PRRT) key companies, revenue, market share, and recent developments.

3. To split the Peptide Receptor Radionuclide Therapy (PRRT) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Peptide Receptor Radionuclide Therapy (PRRT) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Receptor Radionuclide Therapy (PRRT) significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Receptor Radionuclide Therapy (PRRT) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Receptor Radionuclide Therapy (PRRT) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Receptor Radionuclide Therapy (PRRT) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Receptor Radionuclide Therapy (PRRT).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Receptor Radionuclide Therapy (PRRT) industry.

Chapter 3: Detailed analysis of Peptide Receptor Radionuclide Therapy (PRRT) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Peptide Receptor Radionuclide Therapy (PRRT) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Peptide Receptor Radionuclide Therapy (PRRT) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends Table 2. Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers Table 3. Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges Table 4. Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints Table 5. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue Share by Company (2021-2026) Table 7. Global Peptide Receptor Radionuclide Therapy (PRRT) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Peptide Receptor Radionuclide Therapy (PRRT) Key Company Manufacturing Base & Headquarters Table 9. Global Peptide Receptor Radionuclide Therapy (PRRT) Company, Product Type & Application Table 10. Global Peptide Receptor Radionuclide Therapy (PRRT) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Peptide Receptor Radionuclide Therapy (PRRT) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Midgut Neuroendocrine Tumor Table 15. Significant Companies of Gastroenteropancreatic Neuroendocrine Tumor Table 16. Significant Companies of Foregut Neuroendocrine Tumor Table 17. Significant Companies of Hindgut Neuroendocrine Tumor Table 18. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type (2021-2026) Table 22. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacies Table 24. Significant Companies of Online Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application (2021-2026) Table 30. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application (2027-2032) Table 31. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Region (2021-2026) Table 34. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Region (2027-2032) Table 36. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Market Share by Country (2021-2026) Table 39. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Market Share by Country (2027-2032) Table 41. Aurobindo Pharma Company Information Table 42. Aurobindo Pharma Business Overview Table 43. Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 45. Aurobindo Pharma Recent Development Table 46. Curium Pharmaceuticals Company Information Table 47. Curium Pharmaceuticals Business Overview Table 48. Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 50. Curium Pharmaceuticals Recent Development Table 51. Lantheus Company Information Table 52. Lantheus Business Overview Table 53. Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 55. Lantheus Recent Development Table 56. Mundipharma Company Information Table 57. Mundipharma Business Overview Table 58. Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 60. Mundipharma Recent Development Table 61. Bayer Company Information Table 62. Bayer Business Overview Table 63. Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 65. Bayer Recent Development Table 66. Novartis Company Information Table 67. Novartis Business Overview Table 68. Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio Table 70. Novartis Recent Development Table 71. Research Programs/Design for This Report Table 72. Authors List of This Report Table 73. Secondary Sources Table 74. Primary Sources List of Figures Figure 1. Peptide Receptor Radionuclide Therapy (PRRT) Product Image Figure 2. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide Receptor Radionuclide Therapy (PRRT) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Midgut Neuroendocrine Tumor Image Figure 8. Gastroenteropancreatic Neuroendocrine Tumor Image Figure 9. Foregut Neuroendocrine Tumor Image Figure 10. Hindgut Neuroendocrine Tumor Image Figure 11. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacies Image Figure 15. Online Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application (2021-2032) Figure 20. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032) & (US$ Million) Figure 23. North America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032) & (US$ Million) Figure 29. South America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Midgut Neuroendocrine Tumor
  • Gastroenteropancreatic Neuroendocrine Tumor
  • Foregut Neuroendocrine Tumor
  • Hindgut Neuroendocrine Tumor
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Aurobindo Pharma
  • Curium Pharmaceuticals
  • Lantheus
  • Mundipharma
  • Bayer
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Peptide Receptor Radionuclide Therapy (PRRT) Market Dynamics
  1. 2.1 Peptide Receptor Radionuclide Therapy (PRRT) Industry Trends
  2. 2.2 Peptide Receptor Radionuclide Therapy (PRRT) Industry Drivers
  3. 2.3 Peptide Receptor Radionuclide Therapy (PRRT) Industry Opportunities and Challenges
  4. 2.4 Peptide Receptor Radionuclide Therapy (PRRT) Industry Restraints
3 Peptide Receptor Radionuclide Therapy (PRRT) Market by Company
  1. 3.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Ranking (2024-2026)
  4. 3.4 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Manufacturing Base and Headquarters
  5. 3.5 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Product Type and Application
  6. 3.6 Global Peptide Receptor Radionuclide Therapy (PRRT) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Peptide Receptor Radionuclide Therapy (PRRT) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Peptide Receptor Radionuclide Therapy (PRRT) Market by Type
  1. 4.1 Peptide Receptor Radionuclide Therapy (PRRT) Type Introduction
  2. 4.1.1 Midgut Neuroendocrine Tumor
  3. 4.1.2 Gastroenteropancreatic Neuroendocrine Tumor
  4. 4.1.3 Foregut Neuroendocrine Tumor
  5. 4.1.4 Hindgut Neuroendocrine Tumor
  6. 4.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type
  7. 4.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Type (2021-2032)
  9. 4.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type (2021-2032)
5 Peptide Receptor Radionuclide Therapy (PRRT) Market by Application
  1. 5.1 Peptide Receptor Radionuclide Therapy (PRRT) Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application
  6. 5.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Application (2021-2032)
  8. 5.2.3 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application (2021-2032)
6 Peptide Receptor Radionuclide Therapy (PRRT) Regional Value Analysis
  1. 6.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032)
  7. 6.3.2 North America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032)
  10. 6.4.2 Europe Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032)
  16. 6.6.2 South America Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Country, 2025 VS 2032
7 Peptide Receptor Radionuclide Therapy (PRRT) Country-level Value Analysis
  1. 7.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Peptide Receptor Radionuclide Therapy (PRRT) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Peptide Receptor Radionuclide Therapy (PRRT) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 Curium Pharmaceuticals
  8. 8.2.1 Curium Pharmaceuticals Company Information
  9. 8.2.2 Curium Pharmaceuticals Business Overview
  10. 8.2.3 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Curium Pharmaceuticals Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  12. 8.2.5 Curium Pharmaceuticals Recent Developments
  13. 8.3 Lantheus
  14. 8.3.1 Lantheus Company Information
  15. 8.3.2 Lantheus Business Overview
  16. 8.3.3 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lantheus Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  18. 8.3.5 Lantheus Recent Developments
  19. 8.4 Mundipharma
  20. 8.4.1 Mundipharma Company Information
  21. 8.4.2 Mundipharma Business Overview
  22. 8.4.3 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mundipharma Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  24. 8.4.5 Mundipharma Recent Developments
  25. 8.5 Bayer
  26. 8.5.1 Bayer Company Information
  27. 8.5.2 Bayer Business Overview
  28. 8.5.3 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Bayer Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  30. 8.5.5 Bayer Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Peptide Receptor Radionuclide Therapy (PRRT) Product Portfolio
  36. 8.6.5 Novartis Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst